MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

Completed

Conditions studied: Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia

In brief

A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.

Key facts

Study ID
NCT06212466
Run by
Genetesis Inc.
People needed
136
Starts
2024-06-03
Expected to finish
2025-04-15
Last updated by the study team
2025-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.